High Flow Nasal Therapy in Covid 19 Patient

• Conditions: High Flow Nasal Therapy
• Interventions: Other: high flow nasal therapy

• Registration Number: NCT05094648
• Lead Sponsor: Maha Mahmoud Ahmed

Brief Summary

This study aims to To identify factors that predict success of high flow nasal therapy in covid19 patients .

Detailed Description

Coronavirus disease 2019 (COVID-19) is a potentially fatal infection caused by the novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)\[1\]. The highly contagious nature and exponential spread of SARS-CoV-2, coupled with its potential for a rapid progressto acute respiratory distress syndrome (ARDS), has overwhelmed health care systems globally, contributing to the high mortality rates in early reports \[1,2\].

The initial approach for respiratory support for severe COVID-19 pneumonia centredaround invasive mechanical ventilation and the standard lung protective strategy recommended for ARDS\[3\]. This may have been detrimental to a proportion of patients due to ventilator induced lung injury (VILI) and associated systemic inflammation\[4\]. Furthermore, other strategies to improve oxygenation may be more appropriate in patients with hypoxemic respiratory failure who do not require ventilatorysupport\[4\].

High-flow nasal oxygen (HFNO) is delivered by an air/oxygen blender, an active humidifier, a single heated circuit, and a nasal interface.

It delivers adequately heated and humidified medical gas at flow-rates of up to 60L/min, and is considered to have a number of physiological benefits, including the reduction of anatomical dead space and work of breathing, the provision of a constant fraction of inspired oxygen with adequate humidification and a degree of positive end-expiratory pressure (PEEP) \[5,6\].

Study Timeline

• Status Verified: 2021-10
• Study First Submitted: 2021-10-25
• Study First Submitted QC: 2021-10-25
• Last Update Submitted: 2021-10-25
• Study First Posted: 2021-10-26
• Last Update Posted: 2021-10-26
• Study Start: 2021-11-01
• Primary Completion: 2022-08-31
• Study Completion: 2022-09-30

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• All Patients above 18 y old that will be diagnosed as COVID 19 based on PCR testing, who fulfil criteria that indicate need for high flow nasal therapy.

Exclusion Criteria

• o Children less than 18 y old

  • Oropharyngeal and Nasopharyngeal swap negative patients
  • Patients who will refuse inclusion in the study

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
group A	high flow nasal therapy	Covidpatient Who pass on high flow nasal therapy
group B	high flow nasal therapy	Covidpatient who failed on high flow nasal therapy and need NIV

Primary Outcome Measures

Name	Time	Method
predictors of success of high flow nasal therapy in covid 19 patients	Baseline	This study aims to To identify factors that predict success of high flow nasal therapy in covid19 patients